Abstract | INTRODUCTION: MATERIALS AND METHODS: We identified 55 patients with UrAC treated at our hospital between 1994 and 2017. Patients were staged with CT, bone scintigraphy and/or PET/CT. From 2001 on, cN0M0 patients underwent staging laparoscopy. Ten patients had PM and were treated with CRS/ HIPEC; 35 showed no metastases and underwent local treatment; 10 had distant metastases and received palliative chemotherapy. Disease-specific survival (DSS) rates were estimated using the Kaplan-Meier method and log-rank tests. Postoperative complications represent a secondary outcome. RESULTS: The median follow-up was 96.8 months. Of the CRS/ HIPEC patients, 5 (50%) developed a recurrence; 4 (40%) died of disease. The 2-yr and 5-yr DSS after CRS/ HIPEC were 66.7% and 55.6%, respectively. DSS of the CRS/ HIPEC patients did not significantly differ from DSS of patients without metastases who only underwent curative local treatment and was superior to patients with distant metastases (P = 0.012). The overall complication rate after CRS/ HIPEC was 60%. Major complications (Clavien 3) constituted 20%. The study is limited by its retrospective nature and the small sample size. CONCLUSION: CRS/ HIPEC demonstrates satisfactory long-term oncological outcome for patients with PM of UrAC. It may be offered as a potentially curative treatment option for this group of patients.
|
Authors | Laura S Mertens, Mark A Behrendt, Akash M Mehta, Laura Stokkel, Jeroen de Jong, Henk Boot, Simon Horenblas, Michiel S van der Heijden, Luc M Moonen, Arend G J Aalbers, Wim Meinhardt, Bas W G van Rhijn |
Journal | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
(Eur J Surg Oncol)
Vol. 45
Issue 9
Pg. 1740-1744
(Sep 2019)
ISSN: 1532-2157 [Electronic] England |
PMID | 31003721
(Publication Type: Journal Article)
|
Copyright | Copyright © 2019. Published by Elsevier Ltd. |
Topics |
- Combined Modality Therapy
- Cytoreduction Surgical Procedures
- Female
- Humans
- Hyperthermia, Induced
- Male
- Middle Aged
- Neoplasm Staging
- Palliative Care
- Peritoneal Neoplasms
(mortality, secondary, therapy)
- Postoperative Complications
- Survival Rate
- Urinary Bladder Neoplasms
(mortality, pathology)
|